Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)
Researchers aimed to find the optimal dose and regimen of AKCEA-APO(a)-LRX injected subcutaneously for further clinical development.
Researchers aimed to find the optimal dose and regimen of AKCEA-APO(a)-LRX injected subcutaneously for further clinical development.
PCV13 in adults age <65 years with diabetes could reduce a substantial number of pneumonia hospitalizations.
Treatment algorithms are needed for patients with epilepsy who present with evidence of bone loss.